Pacific Biosciences of California, Inc. PACB
2.24 USD -0.12 (-5.08%)
At closeNov 11, 2026, 5:04 AM EST
2.29 +0.05 +2.30%
Pre-market · Nov 11, 5:04 AM ET
2.12 Day range 2.35
1.07 52-week range 3.44
- YTD
- +19.79%
- 1 year
- +27.27%
News
benzinga.com UBS Maintains Neutral on Pacific Biosciences, Lowers Price Target to $2.7 UBS analyst Doug Schenkel maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $3.05 to $2.7.
seekingalpha.com Pacific Biosciences Q3: Another Revenue Guidance Cut Pacific Biosciences reported mixed Q3 results, with revenues beating reduced estimates but gross margins falling. Despite continually declining street revenue estimates, management was disappointed…
benzinga.com Barclays Maintains Underweight on Pacific Biosciences, Raises Price Target to $2 Barclays analyst Luke Sergott maintains Pacific Biosciences (NASDAQ:PACB) with a Underweight and raises the price target from $1.25 to $2.
benzinga.com Piper Sandler Reiterates Neutral on Pacific Biosciences, Raises Price Target to $3 Piper Sandler analyst David Westenberg reiterates Pacific Biosciences (NASDAQ:PACB) with a Neutral and raises the price target from $2 to $3.
seekingalpha.com Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript
zacks.com Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year…
marketbeat.com What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call Pacific Biosciences of California NASDAQ: PACB reported 6% revenue growth for the third quarter of 2026 as customers adopted its SPRQ-Nx sequencing chemistry, though consumables revenue declined from…
benzinga.com Pacific Biosciences Q3 2026 Earnings Call Transcript Pacific Biosciences (NASDAQ:PACB) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…- benzinga.com Pacific Biosciences Narrows FY2026 Sales Guidance from $155.000M-$165.000M to $155.000M-$160.000M vs $158.871M Est Pacific Biosciences (NASDAQ:PACB) narrows FY2026 sales outlook from $155.000 million-$165.000 million to $155.000 million-$160.000 million vs $158.871 million estimate.
globenewswire.com PacBio Announces Third Quarter 2026 Financial Results MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2026.
benzinga.com 10 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session Gainers Pulmonx (NASDAQ:LUNG) stock increased by 33.1% to $2.63 during Wednesday's regular session. The company's market cap stands at $85.0 million. As per the press release, Q3 earnings came out…
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
benzinga.com PacBio And Verily Health Announce Multi-Year Strategic Collaboration To Integrate PacBio HiFi Sequencing With Verily Health’s Governed Data And AI Platform PacBio (NASDAQ:PACB), developer of the world’s most advanced sequencing technologies, and Verily Health Inc., a healthcare data intelligence company, announced today a multi-year strategic…